Published reports suggest that DNA microarrays identify clinically meaningful subtypes of lung adenocarcinomas not recognizable by other routine tests. This report is an investigation of the reproducibility of the reported tumor subtypes.
INTRODUCTION
Lung cancer is the leading cause of cancer death worldwide. 1 Although a useful term for epidemiologic purposes, lung cancer does not refer to a specific disease, but rather represents a heterogeneous collection of tumors of the lung, bronchus, and pleura. 2 In clinical practice, however, most patients are designated to either the specific histologic diagnosis of small-cell lung carcinoma (SCLC) or the diagnosis of exclusion, non-small-cell lung carcinoma (NSCLC). The distinction, although crude, is useful due to striking differences in disease behavior and response to treatment. 3, 4 The subclassification of the nonspecific diagnosis NSCLC for 80% of lung cancer patients is essential when viewed in light of the push toward targeted cancer therapy. The major histologic subtypes of NSCLC include adenocarcinomas (the most common form of lung cancer), squamous cell lung carcinomas (SQ), and large-cell lung carcinomas (LCLC). 2 Within the category of adenocarcinoma of the lung, expert panels have recognized a number of subtypes and histologic variants. Most notably, the WHO's most recent edition of the Histologic Typing of Lung and Pleural Tumors describes no fewer than 13 diagnostic classifications. 2 With the exception of the tumor subtypes bronchioalveolar carcinoma (BAC) and adenocarcinoma with BAC features and their associated mutations of the epidermal growth factor receptor (EGFR) gene, histologic subtypes and molecular markers have had little impact on clinical practice for NSCLC, with treatment based primarily on clinical stage. [5] [6] [7] Histologic subtypes have demonstrated interobserver variability too high for integration into routine practice, although the new WHO classification scheme offers promise for more reproducible diagnosis. [8] [9] [10] [11] In response to the need to develop useful tumor subtypes, researchers have turned to high-throughput screening assays such as DNA microarrays. These tools allow investigators to measure thousands of potential biomarkers for a given patient or cohort of patients in a single assay. 12 Two types of screening methods exist: either an exploration of genes associated with a specific outcome (ie, survival), or a global survey to elicit dominant patterns of gene expression without regard to a specific outcome, called clustering. When tumors cluster, they share a common biologic base, such as a genetic mutation. In a dramatic example, dominant gene expression patterns have demonstrated breast cancer subtypes reproducibly that mirror clinically important tumors genotypes and phenotypes, including estrogen receptor status, BRCA status, Her2/neu expression, and survival. [13] [14] [15] In the field of lung cancer, microarray analysis by independent investigators has demonstrated a wide variety of potentially clinically important uses, including the ability to distinguish morphologic variants reliably and predict prognosis. However, progress in the field has been slow in terms of clarifying the heterogeneity of tumor behavior, such as has been done extensively in breast cancer. 45 The state of gene expression profiling in lung cancer is probably best summarized by Takeuchi et al 16 : "To date, various groups including our own have reported that expression profiling can recapitulate morphologic classification of NSCLCs, and some studies also showed that adenocarcinomas can be subclassified additionally. However, these previously reported subclassifications vary considerably from study to study, making it difficult to reconcile their findings or reach any definite conclusions."
The challenges in reconciling results across gene expression studies are formidable. There is no consensus on the number of subgroups, with investigators reporting between two and more than six subtypes of adenocarcinomas. Furthermore, in the few cases where genes defining subgroups have been reported, the concordance across studies approaches 0%. Although clinical, molecular, and morphologic characteristics have been reported to vary by subtype, no association has emerged that would allow confident identification of adenocarcinoma subtypes in new data or mapping of subtypes across different studies. In summary, although lung cancer subtypes seem to exist, there is little consensus on their number and nature, and how they might be reidentified in a prospective manner. In our current work, we do not propose to repeat individual clustering analyses reported previously, but rather to build on the collective body of work. We hypothesize that through the use of a standardized and systematic method, clearly identifiable subtypes of lung adenocarcinoma can be demonstrated in multiple independent clinical patient cohorts. We propose that the reproducibility constitutesavalidationofthesetumorsubtypesandweprovidethemeans for future investigators to identify these clinically relevant tumor subtypes in a platform-independent manner.
METHODS

Tumor Samples
Multiple lung carcinoma microarray datasets have reported tumor subtypes, but direct comparisons of gene expression profiling studies have not been reported.
20-22 Therefore, we examined the three largest of these studies from the investigators at the University of Michigan (Michigan; Ann Arbor, MI), Stanford University (Stanford; Stanford, CA), and the Dana-Farber Cancer Institute (Dana-Farber; Boston, MA) reporting subtypes of lung adenocarcinoma as defined by expression profiling, and performed a coordinated analysis. Although the tumor of primary interest in the analysis was adenocarcinoma, other tumor and normal tissues were represented in these arrays, including normal lung (NL), SQ, SCLC, LCLC. Adenocarcinomas with the following characteristics were excluded because they were not universally represented across datasets: lymph node metastases of primary tumors, intrapulmonary metastases, distant metastases, and suspected colon metastases. Tumor morphologic type, including BAC status, was determined at the sponsoring institution for each dataset. It is not possible in these data to distinguish samples with pure BAC from those that might better be described as adenocarcinoma with BAC features. Construction of the histologically comparable cohort as well as links to all phenotype data on all samples is documented in the Supplementary Data (available online at http://www.jco.org).
Microarray Data Analysis
The following microarray platforms were used: Michigan, Affymetrix hu6800 GeneChip (Santa Clara, CA); Dana-Farber, 95av2 GeneChip (Affymetrix GeneChip); and Stanford, printed cDNA array using the IMAGE clone set (printed at Standford University, Stanford, CA; IMAGE clone set, Livermore, CA). All arrays were screened for quality by standard methods and experiments not meeting objectively defined quality thresholds were excluded. Quality screening is described in detail, including accounting of all excluded samples, in the Supplementary Data. Gene expression was computed for the oligonucleotide arrays using the robust multichip averaging method, whereas the Stanford Microarray Database Server (SMD) provided expression values for the cDNA arrays. 46, 47 Arrays from the SMD server were processed as in the original report of the data. 21 To normalize gene expression for cross-platform comparisons, all genes were mean-centered within each sample set.
14,48 Unigene cluster identifiers were used to match the probes and probe sets to their representative genes. 49 Genes present on all three array formats were evaluated for cross-platform reliability using the unbiased method of integrative correlations (ICs).
18,50 Genes with IC coefficients exceeding 2 standard deviations above that expected by chance were considered reliable and used for additional analysis. Links to both raw and processed datasets are available in the Supplementary Data.
Robust clusters or tumor subtypes were selected in a standardized manner independently for each dataset (Fig 1) . We used the consensus clustering method, which incorporates average linkage agglomerative hierarchical clustering using a widely accepted distance measure, 1 -(Pearson's correlation coefficient). 51 Confirmation of the optimal clustering assignments was by the independent clustering method, nonnegative matrix factorization, proposed by Brunet et al. 52 Having assigned all adenocarcinoma samples to their respective consensus clusters, we characterized the groups using the centroid method developed by Sørlie et al (see Appendix; online only).
14 Centroids were prepared for the following groups of samples: each adenocarcinoma consensus cluster subtype within the three cohorts, NL, SCLC, SQ, LCLC, and BAC. When a histologic group was present in multiple sample sets (such as NL), a separate centroid was prepared for each dataset in which it appeared. The NL, SQ, SCLC, LCLC, and BAC centroids were used as common references across platforms. Hierarchical agglomerative clustering and probabilistic clustering were used to detect correlations between centroids using the same distance measure as above.
Subtype Gene Lists
Lists of genes most closely associated with the adenocarcinoma clusters were generated using the statistical analysis of microarrays method (SAM; see Appendix).
53 SAM parameters were set to select genes associated with the subclasses in the one versus all, and all pair-wise comparisons, with a fixed false discovery rate (FDR) of 0.1%. If no genes were selected at an FDR of 0.1%, the criterion was relaxed iteratively until at least 10 genes were selected, with the algorithm recording the FDR at which the target was finally reached. In cases requiring relaxing the FDR, the degree of adjustment was suggested automatically by the delta statistic of the SAM algorithm. The result of this FDR adjustment strategy was that in cases where only a few genes are selected, the FDR was generally low. In cases of sparse data, however, the outcome occasionally was the selection of a large number of genes with a high FDR. Gene lists generated in this way were compared across datasets both in terms of their expected concordance and by the nonparametric methodology known as Gene Set Enrichment Analysis (GSEA; see Appendix).
54 Consensus clustering and GSEA were implemented through GenePattern version 1.3.1 (Cambridge, MA), whereas hazard ratios were calculated using the statistical package SPSS version 11.0.1 (SPSS Inc, Chicago, IL). 55 All other analyses and graphs were performed using the R statistical programming language version 1.9.0 (Vienna, Austria) and Bioconductor version 1.4 (Seattle, WA).
56
RESULTS
Demographic and Sample Characteristics
After exclusion of ineligible patients and array-based quality filtering, 31 Stanford, 72 Michigan, and 128 Dana-Farber adenocarcinomas were available for analysis. Examination of the available clinical covariates demonstrated the cohorts to be of a similar composition overall, although missing data precluded a thorough evaluation of the Stanford samples ( Table 1 ). The distribution of age, smoking, sex, and BAC was remarkably similar for the DanaFarber and Michigan cohorts. There was a trend toward a difference in stage distribution, with 79% of Michigan versus 69% of Dana-Farber samples with stage I or II disease (P ϭ .12). Similarly, K-ras mutants were more common in the Michigan group (46% v 34%; P ϭ .10). The most striking difference between the Michigan and Dana-Farber samples was the percentage of well-differentiated tumors (28% v 14%; P ϭ .02). Also differing by cohort was the strategy by which adenocarcinoma samples were assigned to a subtype in the initial reports of the data. For example, in the Michigan scheme, every patient was slotted to one of three subtypes, whereas the Dana-Farber and Stanford groups left many samples unassigned. Similarly investigators differed in criteria for tumor inclusion in their respective studies. For example, to enrich for tumor-specific RNA, Michigan samples were selected to contain more than 70% tumor nuclei and exclude extensive fibrosis and inflammation. In contrast, the Dana-Farber set included samples with a minimum of 30% tumor nuclei, with estimated percentage tumor recorded in most cases. The difference in inclusion criteria introduces the possibility that clinically and biologically meaningful differences in the cohorts may have been introduced because approximately half of Dana-Farber tumors were composed of samples with less than 70% tumor nuclei. Selection of samples by percent tumor nuclei appears likely to account for differences in tumor grade seen between the cohorts (see Supplementary Data).
Gene Selection
The majority of excluded genes were ineligible because of absence on one or more of the three array platforms. An additional 40% of genes were discarded after being flagged as poorly measured by the SMD server. Of the remaining 2,848 genes, 90% (2,553) were reliable by the IC method and were used for additional analysis. A flow chart is provided in the Supplementary Data to document reasons for gene inclusion/exclusion in the current study.
Consensus Clustering: Identification of Bronchioid, Squamoid, and Magnoid Adenocarcinoma Subtypes
The identification of adenocarcinoma subtypes by hierarchical consensus clustering is shown in Figure 1 , with three tumor subtypes suggested as optimum in each of the three cohorts. The choice of three clusters was confirmed using nonnegative matrix factorization-based consensus clustering (see Supplementary Data). Accordingly, within each cohort every sample was assigned exclusively to one of three subtypes defined by the consensus clusters. The nine centroids generated in this manner (one for each subtype in each dataset), as well as 10 reference centroids (three NL, two SQ, two SCLC, one LCLC, and two BAC), were evaluated for their pair-wise correlations across the 2,553 reliable genes using hierarchical agglomerative clustering (Fig 2) . All centroids of similar histology, including NL, SQ, SCLC, and BAC, each derived from a different data source and array platform, demonstrate high correlation in the branched dendrogram. Similarly, adenocarcinoma subtype centroids demonstrate a strong cross-platform pattern of correlation in the following manner. Each dataset contributed one centroid to a dendrogram branch associated with the BAC centroids, thereby suggesting the cluster name bronchioid. Similarly, each dataset contributed a squamoid adenocarcinoma centroid to a dendrogram branch highly correlated with a SQ centroid. The remaining three adenocarcinoma centroids correlated best with the LCLC, offering the remaining centroid name of magnoid (from the Latin magnus, meaning "large"), although we note that the Michiganderived centroid had an overall lower correlation. The results of tumor subtyping by consensus clustering were compared with results proposed in the original reports of these data in the Supplementary Data. The mapping of consensus clusters to those originally reported documents clear concordance in every case; it also highlights complex idiosyncrasies that impede a direct comparison of nonstandardized clustering.
Clinical and Biologic Correlates of Adenocarcinoma Subtypes
The adenocarcinoma subtypes were characterized by the available clinical and phenotypic data ( Table 2 ). The subtype prevalence was similar across cohorts, with bronchioid and squamoid tumors comprising each around 33% to 52% of samples; the magnoid type comprised a minority at 10% to 26%. The percent tumor nuclei by subtype was highest in the bronchioid group and lowest in the squamoid group. In all three datasets, the squamoid subtype contained a higher percentage of poorly differentiated tumors than the bronchioid adenocarcinomas. Figure 2 suggests by the branch lengths of the dendrogram that the squamoid and magnoid clusters are more closely related to each other than either is to the bronchioid cluster. It is likely that this relationship is at least in part related to the properties they share of overall higher tumor grade and lower percentage tumor nuclei.
Adenocarcinoma subtype did not correlate clearly with stage in any of the datasets. All but one tumor with mucin was found in the bronchioid cluster. Clear cell histology was noted in four samples, none of which were of the bronchioid subtype. Interestingly, there was an over-representation of females, nonsmokers, and BAC histology in the bronchioid relative to the squamoid adenocarcinomas. Of all samples with any BAC histologic features reported in the pathologist's description, 75% fell within the bronchioid cluster. Accordingly, the highest percentage of epidermal growth factor receptor (EGFR) mutations was found in the bronchioid subtype (15%), with only one of 33 magnoid samples having an EGFR mutation. The single mutation found in the magnoid subgroup occurred in an extracellular domain of the gene not associated with responsiveness to EGFR inhibitors (unpublished data). Although the 2 P value failed to meet statistical testing for a difference in proportion of EGFR mutation by tumor subtype (P ϭ .21), a trend was noted for the comparison of bronchioid versus magnoid (P ϭ .08). Moreover, although not statistically significant, increased frequency of mutated K-ras was noted in the squamoid subtype relative to the bronchioid (30% v 37%; P ϭ .3).
Kaplan-Meier curves were generated to assess differences in survival by adenocarcinoma subtype (Fig 3) . Only the Dana-Farber group had sufficient follow-up and numbers of events to calculate curves for stage I and II patients. In these patients, the squamoid and magnoid subtypes demonstrated significantly shorter survival compared with the bronchioid tumors, with hazard ratios (HRs) of 3.6 (P ϭ .01) and HR 3.0 (P ϭ .04), respectively. After stratifying by stage, we evaluated all clinical covariates available in these data by multivariate Cox proportional hazards modeling for association with survival, including age, differentiation, sex, smoking status, BAC histology, K-ras mutations status, and EGFR mutation status. In both the univariate and multivariate analysis, only tumor subtype, age, and differentiation were significantly associated with survival. Strikingly, in advanced and nonsurgical disease (stages III and IV), the survival advantage is reversed with a trend toward improved survival in the squamoid subtype relative to the magnoid (HR, 0.32; P ϭ .03) and bronchioid subtypes (HR, 0.58; P ϭ .2). There were too few samples to perform meaningful multivariate adjustment in advanced-stage patients. Evaluating all eligible patients without regard to stage, survival was worse in magnoid tumors compared with both bronchioid (HR, 1.7; P ϭ .04.) and squamoid (HR, ϭ 1.6; P ϭ .10) tumors. Absent consideration of stage, survival in the squamoid versus bronchioid tumors essentially is identical (HR, 1.1; P ϭ .70).
Differential survival by tumor subtype was confirmed in two independent cohorts of early-stage lung adenocarcinoma patients treated by surgery alone using identical methods to those described above (see Fig 4 and Supplementary Data). The first was a group of 41 patients treated at Duke University whose tumors were assayed using the Affymetrix u1332plus GeneChip with approximately 47,000 transcripts. 57 As in the Dana-Farber example, the squamoid and magnoid subtypes demonstrated inferior survival compared with the bronchioid (HR, 8.1; P Ͻ .001 and HR, 9.7; P Ͻ .001, respectively). The second cohort of 86 patients was constructed at the University of British Columbia for the purpose of evaluating 18 immunohistochemical markers in non-small-cell lung cancer patients using a tissue microarray format and has been described in detail elsewhere. 58 These data were particularly interesting because the markers measured proteins as opposed to gene expression. Yet again, the results were consistent, with the squamoid and magnoid subtypes demonstrating clear trends toward inferior survival compared with the bronchioid samples (HR, 2.7; P ϭ .06 and HR, 2.2; P ϭ .16, respectively).
Incidence and site of distant recurrence were available for earlystage tumors from the Dana-Farber cohort. Of 74 patients with stage I disease, 28 patients (38%) had a recurrence reported in the study period. Both the pattern and rate of recurrence varied by tumor subtype, however, with 27% of patients with bronchioid, 61% of patients with squamoid, and 37% of patients with magnoid subtypes reporting a recurrence (P ϭ .04). Interestingly, five of six patients with bronchioid tumors and distant metastases reported bone involvement, representing 63% of all bone recurrences in these data. Finally, five of nine patients with squamoid tumors and distant metastases reported brain involvement, representing 71% of all brain recurrences.
Genes Associated With Subtypes
For each dataset, all possible one group versus all groups, and all pair-wise comparisons were evaluated by the SAM methodology, generating the 36 gene lists described in Table 3 . The genes corresponding As expected, the number of differentially expressed genes correlated with the numbers of patients in the cohort. Of interest, considerably fewer genes per hypothesis tested were identified in the Stanford group even after accounting for cohort size; this result probably reflects technical features of gene expression measurement in the Stanford microarray platform. Gene lists derived from the Michigan data were comparable in length to those from the Dana-Farber group, with the exception of those for the magnoid subtype, which were shortened and had higher FDRs. The SAM-generated lists were examined for concordance (Table  4 ). In 28 of 36 comparisons, the concordance across gene lists was greater than expected by chance. Of those for which concordance was not greater than expected by chance, five of eight involved the Michigan magnoid subtype. GSEA was performed to test the statistical significance of SAM-generated gene lists as independent predictors of tumor subtypes across studies (Table 5) . Of the 72 gene lists validated, there was evidence supporting cross-platform validation in 59. Of the 13 lists that failed to validate by these criteria, nine involved the Michigan magnoid subtype, demonstrating its weak signature in these data.
Biologic Pathways of Tumor Subtypes
Although an explicit evaluation of the tumor subtype biology is outside the scope of this article, a brief consideration clearly is warranted (Table 6 ). Bronchioid tumors were dominated by a program of growth, development, differentiation, and survival genes. Defining genes of the squamoid tumors stem from a dramatically different set of tumor processes, including angiogenesis such as hypoxia-inducible factor-1-alpha, transforming growth factor beta pathway genes, and the WNT signaling cascade. Magnoid tumors demonstrate a pattern of gene expression associated with a distinct set of pathways, primarily inflammation, cytoskeleton, metabolism, and proliferation. In addition, of clinical interest we note that the three subtypes differ with respect to a number of putative markers of cancer chemotherapy and radiation treatment. Of particular note, the bronchioid subtype is associated with the majority of genes associated with cisplatin resistance. A more in-depth review of these genes is provided in the Supplementary Data.
DISCUSSION
The hypothesis tested for the first time in the current work is that lung adenocarcinoma subtypes defined by gene array analysis are reproducible and clinically relevant. The adenocarcinoma subtypes we report were identified in an unbiased, independent, and objective manner, and are distinct in cross-platform validation by correlation with expression patterns from recognized lung tumor histologic subtypes (BAC, LCLC, SQ, and SCC). Furthermore, reproducible subtypes can be identified through the use of centroids even in the absence of a gold standard reference such as a molecular marker or an a priori predictive gene list. Tumor subtypes were named according to overall similarity of gene expression patterns across hundreds or thousands of genes to easily recognizable morphologic lung cancer variants. This naming choice emphasizes the view that the tumor subtypes are not dependent on identification of a fixed set of genes, specific analytic method, or microarray platform, and allows future investigators to establish a common reference point lacking in this heterogeneous disease. NOTE. The column heading names the dataset that generated the gene list, followed by the cohort in which the list was validated. The ES sign (ϩ or Ϫ) denotes the direction of correlation of the gene list with the tumor subtype distinction named in the row (see Methods and Appendix). Abbreviation: ES, enrichment score.
‫ء‬
Evidence for validation, ES score positive, permutation P significant. †Evidence for validation, ES score positive, permutation P trending toward significance (.1 to .25). ‡Evidence for validation, ES score positive, permutation P Ͼ .25. §Evidence against validation, ES score negative, permutation P not significant. ʈEvidence against validation, ES score negative, permutation P significant. defining the bronchioid subtype were more likely to be those correlated with chemotherapy and radiation resistance. Bronchioid tumors were of overall lower tumor grade, tended to demonstrate markers of type II pneumocyte differentiation, and stain positively for mucin production. In contrast, squamoid tumors were more likely from male smokers in tumors with K-ras gene mutation. Patients with squamoid tumors fared significantly worse that those with the bronchioid subtype in early-stage disease, but better in advanced disease. The poor prognosis in earlier stages is likely due to a tendency to metastasize early, including a higher likelihood of brain involvement. Squamoid adenocarcinomas were more likely to be moderately or poorly differentiated and to be associated with genes most commonly associated with squamous cell carcinoma. Gene list predictors of squamoid and bronchioid subtypes were generated independently for each subtype in each cohort, and in every case these were validated by the GSEA and centroid methodologies. A third group, the magnoid subtype, was also selected in each of the three independent cohorts by the objective method we describe. Magnoid tumors were the most infrequent, ranging from 10% in the Michigan cohort to 26% in the Dana-Farber samples. One of the most pronounced characteristics of the magnoid subtype was the strong inflammatory signature. Presumably, because the exclusion criteria for the Michigan cohort included significant numbers of inflammatory cells, this would reduce the percentage of magnoid tumors in this cohort. As a result, although all three cohorts detect the magnoid cluster, both the gene expression and clinical profile are less distinct than for the bronchioid and squamoid tumors, although the overall poor prognosis of the group was statistically significant in advanced disease.
The expression patterns defining the tumor subtypes presented are not subtle statistical phenomena dependent on a handful of predictive genes. Forty percent of all reliable genes in the dataset were predictive of at least one adenocarcinoma subtype using the criteria we established in the Methods section. Amazingly, the expression signature extends beyond even these 1,066 genes selected by SAM. When all genes selected as predictors of the tumor subtypes are excluded and the current analysis repeated, we obtain essentially identical results (data not shown). In other words, many genes failing to meet significance testing will contribute signal to the tumor subtype identity by the centroid method analysis.
By focusing on standardized and unbiased methods, we essentially have excluded the possibility that adenocarcinoma subtypes are the result of chance, noise, artifact, or analytic method. None of the analytic parameters, including sample selection, gene selection, optimal cluster number, and cluster assignment, were optimized with regard to the study outcome. In each case, analytic methods were based on a priori biologic and statistical considerations. Although unrecognized technical artifacts can drive clustering patterns in a single dataset, it is unlikely that similar effects would be present in multiple cohorts using different assay platforms, as was the case here. It is even less likely that spurious clusters would correlate with the constellations of clinical features across three datasets in the manner described in this study. In addition, our standardized analysis agreed well with the previously published results, but also clarified the findings for meaningful comparison that would not otherwise be possible. Finally, we demonstrate the ability to evaluate tumor subtypes with confidence and ease in a platform-independent manner, as we did with the expression arrays from Duke and the tissue microarrays from the University of British Columbia.
Although a specific discussion of genes and biologic pathways is beyond the scope of this work, all of the data, including the lists of genes associated with each of the subtypes, are available in the Supplementary Data. Regarding the cancer pathways associated with the tumor subtypes, our results mirror those of the previously published reports. [20] [21] [22] The importance of tumor subtyping is clear even in the absence of a complete biologic understanding. Tumor subtype is suggested as a proxy for at least one important mutation (EGFR), with none of the magnoids demonstrating the clinically meaningful finding. It is likely that other important genomic events are conferred by tumor subtype membership, including specific chromosomal abnormalities (results not shown).
The main focus of this analysis was the validation of adenocarcinoma subtypes derived from clustering of expression profiles. We chose to validate three subtypes, given that this was the number suggested by consensus clustering. It is striking that, in the face of what is considered a heterogeneous tumor, three clusters emerged consistently, suggesting that a molecular taxonomy could be proposed that is simple, reproducible, and complementary to light microscopy alone. We do not exclude the possibility that additional tumor subtypes might be described if the sample set were larger or of a different composition. A group of investigators funded under the National Institutes of Health's Directors Challenge Program recently has completed processing of several hundred new lung cancer expression arrays. It is hoped that the validation of lung adenocarcinoma subtypes in the current report in conjunction with these new data will expedite more reliable classification of the heterogeneous group of tumors currently known most frequently as NSCLC.
